The Influence of Heart Failure Self-care on Health Outcomes:Hypothetical Cardioprotective Mechanisms

Journal of Cardiovascular Nursing

Volumn 24, Issue 3, 2009, Pages 179-187

  Lee, Christopher S ^a   Tkacs, Nancy C ^a   Riegel, Barbara ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Adherence; Heart failure; Physiology; Self care; Symptom management

Indexed keywords

AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; CYTOKINE;

DISEASE COURSE; DISEASE MANAGEMENT; HEALTH BEHAVIOR; HEART FAILURE; HOMEOSTASIS; HUMAN; INFECTION CONTROL; INFLAMMATION; KINESIOTHERAPY; METHODOLOGY; NURSE ATTITUDE; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PATIENT EDUCATION; PHYSIOLOGY; PSYCHOLOGICAL ASPECT; REVIEW; SELF CARE; SODIUM RESTRICTION; STUNNED HEART MUSCLE; TREATMENT OUTCOME;

CYTOKINES; DIET, SODIUM-RESTRICTED; DISEASE MANAGEMENT; DISEASE PROGRESSION; EXERCISE THERAPY; HEALTH BEHAVIOR; HEART FAILURE; HOMEOSTASIS; HUMANS; INFECTION CONTROL; INFLAMMATION; MYOCARDIAL STUNNING; NEUROTRANSMITTER AGENTS; NURSE'S ROLE; PATIENT COMPLIANCE; PATIENT EDUCATION AS TOPIC; SELF CARE; TREATMENT OUTCOME;

EID: 67650287229     PISSN: 08894655     EISSN: 15505049     Source Type: Journal    
DOI: 10.1097/JCN.0b013e31819b5419     Document Type: Article

References (73)

1. Lainscak M, Cleland JG, Lenzen MJ, et al. Nonpharmacologic measures and drug compliance in patients with heart failure: data from the EuroHeart Failure Survey. Am J Cardiol. 2007;99(6B):31D-37D.
2. Hauptman PJ. Medication adherence in heart failure. Heart Fail Rev. 2008;13(1):99-106.
3. Michalsen A, Konig G, Thimme W. Preventable causative factors leading to hospital admission with decompensated heart failure. Heart. 1998;80(5):437-441.
4. Rockwell JM, Riegel B. Predictors of self-care in persons with heart failure. Heart Lung. 2001;30(1):18-25.
5. Riegel B, Carlson B, Glaser D. Development and testing of a clinical tool measuring self-management of heart failure. Heart Lung. 2000;29(1):4-15.
6. Cleemput I, Kesteloot K. Economic implications of non-compliance in health care. Lancet. 2002;359(9324):2129-2130.
7. Riegel B, Dickson VV. A situation-specific theory of heart failure self-care. J Cardiovasc Nurs. 2008;23(3):190-196.
8. Riegel B, Carlson B, Moser DK, Sebern M, Hicks FD, Roland V. Psychometric testing of the self-care of heart failure index. J Card Fail. 2004;10(4):350-360.
9. Jaarsma T, Abu-Saad HH, Dracup K, Halfens R. Self-care behaviour of patients with heart failure. Scand J Caring Sci. 2000;14(2):112-119.
10. Gaze DC. The role of existing and novel cardiac biomarkers for cardioprotection. Curr Opin Investig Drugs. 2007;8(9):711-717.
11. Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol. 1992;20(1):248-254.
12. Davila DF, Nunez TJ, Odreman R, de Davila CA. Mechanisms of neurohormonal activation in chronic congestive heart failure: pathophysiology and therapeutic implications. Int J Cardiol. 2005;101(3):343-346.
13. Gheorghiade M, Shin DD, Thomas TO, Brandimarte F, Fonarow GC, Abraham WT. Congestion is an important diagnostic and therapeutic target in heart failure. Rev Cardiovasc Med. 2006;7(suppl 1):S12-S24.
14. Katz AM. Heart failure: a hemodynamic disorder complicated by maladaptive proliferative responses. J Cell Mol Med. 2003;7(1):1-10.
15. Lee CS, Tkacs NC. Current concepts of neurohormonal activation in heart failure: mediators and mechanisms. AACN Adv Crit Care. 2008;19(4):364-385.
16. Schweda F, Segerer F, Castrop H, Schnermann J, Kurtz A. Blood pressure-dependent inhibition of Renin secretion requires A1 adenosine receptors. Hypertension. 2005;46(4):780-786.
17. Persson PB. Renin: origin, secretion and synthesis. J Physiol. 2003;552(pt 3):667-671.
18. Cruden NL, Fox KA, Ludlam CA, Johnston NR, Newby DE. Neutral endopeptidase inhibition augments vascular actions of bradykinin in patients treated with angiotensin-converting enzyme inhibition. Hypertension. 2004;44(6):913-918.
19. Chen HH, Schrier RW. Pathophysiology of volume overload in acute heart failure syndromes. Am J Med. 2006;119(12 suppl 1):S11-S16.
20. Ferrario CM, Strawn WB. Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease. Am J Cardiol. 2006;98(1):121-128.
21. Lennie TA. Nutrition self-care in heart failure: state of the science. J Cardiovasc Nurs. 2008;23(3):197-204.
22. Bennett SJ, Huster GA, Baker SL, et al. Characterization of the precipitants of hospitalization for heart failure decompensation. Am J Crit Care. 1998;7(3):168-174.
23. Tsuyuki RT, McKelvie RS, Arnold JM, et al. Acute precipitants of congestive heart failure exacerbations. Arch Intern Med. 2001;161(19):2337-2342.
24. Schrier RW, Abraham WT. Hormones and hemodynamics in heart failure. N Engl J Med. 1999;341(8):577-585.
25. Jurgens CY. Somatic awareness, uncertainty, and delay in care-seeking in acute heart failure. Res Nurs Health. 2006;29(2):74-86.
26. Evangelista LS, Dracup K, Doering LV. Treatment-seeking delays in heart failure patients. J Heart Lung Transplant. 2000;19(10):932-938.
27. Alvelos M, Ferreira A, Bettencourt P, et al. The effect of dietary sodium restriction on neurohumoral activity and renal dopaminergic response in patients with heart failure. Eur J Heart Fail. 2004;6(5):593-599.
28. Patel J, Smith M, Heywood JT. Optimal use of diuretics in patients with heart failure. Curr Treat Options Cardiovasc Med. 2007;9(4):332-342.
29. Nieminen MS, Bohm M, Cowie MR, et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J. 2005;26(4):384-416.
30. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344(22):1651-1658.
31. Holmes CL, Landry DW, Granton JT. Science review: vasopressin and the cardiovascular system, part 2: clinical physiology. Crit Care. 2004;8(1):15-23.
32. Haynes WG, Webb DJ. Endothelin as a regulator of cardiovascular function in health and disease. J Hypertens. 1998;16(8):1081-1098.
33. Attina T, Camidge R, Newby DE, Webb DJ. Endothelin antagonism in pulmonary hypertension, heart failure, and beyond. Heart. 2005;91(6):825-831.
34. Nessler J, Nessler B, Kitlinski M, Gackowski A, Piwowarska W, Stepniewski M. Concentration of BNP, endothelin 1, pro-inflammatory cytokines (TNF-alpha, IL-6) and exercise capacity in patients with heart failure treated with carvedilol. Kardiol Pol. 2008;66(2):144-151.
35. Ruskoaho H. Cardiac hormones as diagnostic tools in heart failure. Endocr Rev. 2003;24(3):341-356.
36. Sharma JN. The kallikrein-kinin system: from mediator of inflammation to modulator of cardioprotection. Inflammopharmacology. 2005;12(5-6):591-596.
37. Seta Y, Shan K, Bozkurt B, Oral H, Mann DL. Basic mechanisms in heart failure: the cytokine hypothesis. J Card Fail. 1996;2(3):243-249.
38. Gullestad L, Aukrust P. Review of trials in chronic heart failure showing broad-spectrum anti-inflammatory approaches. Am J Cardiol. 2005;95(11A):17C-23C>; discussion 38C-40C>.
39. World CJ, Garin G, Berk B. Vascular shear stress and activation of inflammatory genes. Curr Atheroscler Rep. 2006;8(3):240-244.
40. Aukrust P, Gullestad L, Ueland T, Damas JK, Yndestad A. Inflammatory and anti-inflammatory cytokines in chronic heart failure: potential therapeutic implications. Ann Med. 2005;37(2):74-85.
41. Nian M, Lee P, Khaper N, Liu P. Inflammatory cytokines and postmyocardial infarction remodeling. Circ Res. 2004;94(12):1543-1553.
42. von Haehling S, Jankowska EA, Anker SD. Tumour necrosis factor-alpha and the failing heart-pathophysiology and therapeutic implications. Basic Res Cardiol. 2004;99(1):18-28.
43. Kanda T, Takahashi T. Interleukin-6 and cardiovascular diseases. Jpn Heart J. 2004;45(2):183-193.
44. Mann DL. Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res. 2002;91(11):988-998.
45. Lopez Farre A, Casado S. Heart failure, redox alterations, and endothelial dysfunction. Hypertension. 2001;38(6):1400-1405.
46. Cinquegrana G, D'Aniello L, Landi M, et al. Effects of different degrees of sympathetic antagonism on cytokine network in patients with ischemic dilated cardiomyopathy. J Card Fail. 2005;11(3):213-219.
47. Mayer B, Holmer SR, Hengstenberg C, Lieb W, Pfeifer M, Schunkert H. Functional improvement in heart failure patients treated with beta-blockers is associated with a decline of cytokine levels. Int J Cardiol. 2005;103(2):182-186.
48. Montebugnoli L, Servidio D, Miaton RA, Prati C, Tricoci P, Melloni C. Poor oral health is associated with coronary heart disease and elevated systemic inflammatory and haemostatic factors. J Clin Periodontol. 2004;31(1):25-29.
49. Sandoval C, Walter SD, Krueger P, et al. Risk of hospitalization during influenza season among a cohort of patients with congestive heart failure. Epidemiol Infect. 2007;135(4):574-582.
50. Nichol KL, Nordin J, Mullooly J, Lask R, Fillbrandt K, Iwane M. Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly. N Engl J Med. 2003;348(14):1322-1332.
51. Rauchhaus M, Doehner W, Francis DP, et al. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation. 2000;102(25):3060-3067.
52. Peschel T, Schonauer M, Thiele H, Anker SD, Schuler G, Niebauer J. Invasive assessment of bacterial endotoxin and inflammatory cytokines in patients with acute heart failure. Eur J Heart Fail. 2003;5(5):609-614.
53. Wielenga RP, Huisveld IA, Bol E, et al. Safety and effects of physical training in chronic heart failure. Results of the Chronic Heart Failure and Graded Exercise study (CHANGE). Eur Heart J. 1999;20(12):872-879.
54. McKelvie RS, Teo KK, Roberts R, et al. Effects of exercise training in patients with heart failure: the Exercise Rehabilitation Trial (EXERT). Am Heart J. 2002;144(1):23-30.
55. Hambrecht R, Wolf A, Gielen S, et al. Effect of exercise on coronary endothelial function in patients with coronary artery disease. N Engl J Med. 2000;342(7):454-460.
56. O'Rourke ST. Antianginal actions of beta-adrenoceptor antagonists. Am J Pharm Educ. 2007;71(5):95.
57. Katz AM. Physiology of the Heart. 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2006.
58. Fonarow GC. Acute decompensated heart failure: challenges and opportunities. Rev Cardiovasc Med. 2007;8(suppl 5):S3-12.
59. Domanski M, Tian X, Haigney M, Pitt B. Diuretic use, progressive heart failure, and death in patients in the DIG study. J Card Fail. 2006;12(5):327-332.
60. Ahmed A, Husain A, Love TE, et al. Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using propensity score methods. Eur Heart J. 2006;27(12):1431-1439.
61. Eshaghian S, Horwich TB, Fonarow GC. Relation of loop diuretic dose to mortality in advanced heart failure. Am J Cardiol. 2006;97(12):1759-1764.
62. Hasselblad V, Gattis Stough W, Shah MR, et al. Relation between dose of loop diuretics and outcomes in a heart failure population: results of the ESCAPE trial. Eur J Heart Fail. 2007;9(10):1064-1069.
63. Bayram M, De Luca L, Massie MB, Gheorghiade M. Reassessment of dobutamine, dopamine, and milrinone in the management of acute heart failure syndromes. Am J Cardiol. 2005;96(6A):47G-58G.
64. Cuffe MS, Califf RM, Adams KF Jr, et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA. 2002;287(12):1541-1547.
65. Felker GM, Benza RL, Chandler AB, et al. Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. J Am Coll Cardiol. 2003;41(6):997-1003.
66. O'Connor CM, Gattis WA, Uretsky BF, et al. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). Am Heart J. 1999;138(1 pt 1):78-86.
67. Metra M, Torp-Pedersen C, Cleland JG, et al. Should beta-blocker therapy be reduced or withdrawn after an episode of decompensated heart failure? Results from COMET. Eur J Heart Fail. 2007;9(9):901-909.
68. Webel AR, Frazier SK, Lennie T, Moser DK. Daily variability in dyspnea, edema and body weight in heart failure patients. Eur J Cardiovasc Nurs. 2006;6(1):60-65.
69. Jurgens CY, Fain JA, Riegel B. Psychometric testing of the Heart Failure Somatic Awareness Scale. J Cardiovasc Nurs. 2006;21(2):95-102.
70. Wijns W, Vatner SF, Camici PG. Hibernating myocardium. N Engl J Med. 1998;339(3):173-181.
71. Bhatia G, Sosin M, Leahy JF, Connolly DL, Davis RC, Lip GY. Hibernating myocardium in heart failure. Expert Rev Cardiovasc Ther. 2005;3(1):111-122.
72. Selvanayagam JB, Jerosch-Herold M, Porto I, et al. Resting myocardial blood flow is impaired in hibernating myocardium: a magnetic resonance study of quantitative perfusion assessment. Circulation. 2005;112(21):3289-3296.
73. Cleland JG, Pennell DJ, Ray SG, et al. Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): randomised controlled trial. Lancet. 2003;362(9377):14-21.